KR20110016952A - Mybl2 에피토프 펩티드 및 이를 포함하는 백신 - Google Patents

Mybl2 에피토프 펩티드 및 이를 포함하는 백신 Download PDF

Info

Publication number
KR20110016952A
KR20110016952A KR1020107028961A KR20107028961A KR20110016952A KR 20110016952 A KR20110016952 A KR 20110016952A KR 1020107028961 A KR1020107028961 A KR 1020107028961A KR 20107028961 A KR20107028961 A KR 20107028961A KR 20110016952 A KR20110016952 A KR 20110016952A
Authority
KR
South Korea
Prior art keywords
leu
peptide
ser
lys
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107028961A
Other languages
English (en)
Korean (ko)
Inventor
타쿠야 츠노다
류지 오사와
Original Assignee
온코세라피 사이언스 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코세라피 사이언스 가부시키가이샤 filed Critical 온코세라피 사이언스 가부시키가이샤
Publication of KR20110016952A publication Critical patent/KR20110016952A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020107028961A 2008-06-10 2009-06-09 Mybl2 에피토프 펩티드 및 이를 포함하는 백신 Ceased KR20110016952A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6029308P 2008-06-10 2008-06-10
US61/060,293 2008-06-10

Publications (1)

Publication Number Publication Date
KR20110016952A true KR20110016952A (ko) 2011-02-18

Family

ID=41416535

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028961A Ceased KR20110016952A (ko) 2008-06-10 2009-06-09 Mybl2 에피토프 펩티드 및 이를 포함하는 백신

Country Status (13)

Country Link
US (1) US20110189213A1 (enExample)
EP (1) EP2297180A4 (enExample)
JP (1) JP2011522777A (enExample)
KR (1) KR20110016952A (enExample)
CN (1) CN102119170A (enExample)
AU (1) AU2009258775B2 (enExample)
BR (1) BRPI0913436A2 (enExample)
CA (1) CA2727482A1 (enExample)
IL (1) IL209870A0 (enExample)
MX (1) MX2010013688A (enExample)
RU (1) RU2496787C2 (enExample)
TW (1) TW201000119A (enExample)
WO (1) WO2009150822A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201200525A (en) * 2009-12-04 2012-01-01 Oncotherapy Science Inc MYBL2 peptides and vaccines containing the same
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
CN104017054B (zh) * 2014-06-25 2016-12-07 南安市威速电子科技有限公司 Per2蛋白激动剂多肽及其应用
CN104004062B (zh) * 2014-06-25 2016-03-16 刘元超 关于per2蛋白激动剂多肽及其应用
CN104045693B (zh) * 2014-06-25 2016-12-07 杨高林 一种关于per2蛋白激动剂多肽及其应用
WO2017194170A1 (en) * 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
WO2017203370A2 (en) * 2016-05-23 2017-11-30 The Council Of The Queensland Institute Of Medical Research Cmv epitopes
CN109963862B (zh) * 2016-09-07 2024-01-30 武汉华大吉诺因生物科技有限公司 多肽及其应用
CN109136376B (zh) * 2018-05-21 2021-09-21 中国医科大学附属第四医院 一种膀胱癌相关环状RNA的应用和siRNA及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0253486A (ja) * 1988-08-19 1990-02-22 Rikagaku Kenkyusho ヒトmyb関連遺伝子
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
WO2004018667A1 (ja) * 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha ペプチド及びこれを含む医薬
CN101139392B (zh) * 2002-09-12 2012-12-26 肿瘤疗法科学股份有限公司 Kdr肽和包括该肽的疫苗
CN1703522A (zh) * 2002-09-30 2005-11-30 肿瘤疗法科学股份有限公司 诊断睾丸精原细胞瘤的方法
US20050260639A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
EP2947160B1 (en) * 2004-04-09 2017-07-12 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
JP2008511678A (ja) * 2004-09-02 2008-04-17 イェール ユニバーシティ マイクロrnaによるオンコジーンの調節
ES2319286T3 (es) * 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
AU2005304878B2 (en) * 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
CN101500597A (zh) * 2005-06-17 2009-08-05 伊姆克罗尼系统公司 治疗转移性骨癌的受体拮抗剂
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
EP2295571A1 (en) * 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007066423A1 (ja) * 2005-12-08 2007-06-14 Dainippon Sumitomo Pharma Co., Ltd. Amacr由来の腫瘍抗原ペプチド
JP2009091249A (ja) * 2006-01-23 2009-04-30 Univ Kurume C型肝炎ウイルス2a由来HLA−A2拘束性抗原ペプチド
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer

Also Published As

Publication number Publication date
JP2011522777A (ja) 2011-08-04
US20110189213A1 (en) 2011-08-04
TW201000119A (en) 2010-01-01
MX2010013688A (es) 2011-02-23
CN102119170A (zh) 2011-07-06
EP2297180A4 (en) 2011-11-09
CA2727482A1 (en) 2009-12-17
AU2009258775B2 (en) 2013-10-10
BRPI0913436A2 (pt) 2015-12-01
RU2496787C2 (ru) 2013-10-27
IL209870A0 (en) 2011-02-28
RU2010154101A (ru) 2012-07-20
AU2009258775A1 (en) 2009-12-17
EP2297180A1 (en) 2011-03-23
WO2009150822A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
KR101705011B1 (ko) Cdca1 에피토프 펩티드 및 이를 포함하는 백신
JP5320544B2 (ja) Tem8ペプチドおよびそれを含むワクチン
WO2010021111A1 (en) Inhbb epitope peptides and vaccines containing the same
RU2496787C2 (ru) Пептиды эпитопов mybl2 и содержащие их вакцины
WO2009150835A1 (en) Iqgap3 epitope peptides and vaccines containing the same
KR101705514B1 (ko) Melk 에피토프 펩티드 및 이를 포함하는 백신
KR20110045052A (ko) Hig2 및 urlc10 에피토프 펩티드 및 이를 포함하는 백신
KR101705102B1 (ko) Wdrpuh 에피토프 펩티드 및 이를 포함하는 백신
AU2008238739B2 (en) TEM8 peptides and vaccines comprising the same
HK1155757A (en) Cdca1 epitope peptides and vaccines containing the same
HK1155757B (en) Cdca1 epitope peptides and vaccines containing the same
HK1156341B (en) Melk epitope peptides and vaccines containing the same
HK1175197B (en) Tem8 peptides and vaccines comprising the same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160218

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I